Skip to main content
Medrx Co.,Ltd. logo

Medrx Co.,Ltd. — Investor Relations & Filings

Ticker · 4586 ISIN · JP3921220004 T Manufacturing
Open in API
Filings indexed 79 across all filing types
Latest filing 2026-05-20 Share Issue/Capital Cha…
Country JP Japan
Listing T 4586

About Medrx Co.,Ltd.

https://www.medrx.co.jp/english/

Medrx Co., Ltd. is a pharmaceutical formulation development company that specializes in creating new dosage forms of medicines. The company's core focus is its transdermal absorption technology, which is used to develop innovative drug delivery systems like patches. These products are designed to improve patient health and quality of life (QOL) by providing alternatives for medications that are difficult to administer orally or by helping to prevent patients from forgetting to take their medicine. Medrx is actively engaged in research and development, managing a pipeline of pharmaceutical candidates that utilize its proprietary formulation technologies.

Recent filings

Filing Released Lang Actions
第三者割当てによる第35回新株予約権(行使価額修正条項付)の発行及び第三者割当契約等の締結に関するお知らせ
Share Issue/Capital Change Classification · 90% confidence The document is a formal announcement by a listed Japanese company (code: 4586) disclosing the issuance of the 35th series of stock acquisition rights (new share subscription warrants) through a third-party allotment and the conclusion of related agreements. It details the issuance terms, allotment date, number of warrants, issue price, potential dilution, use of proceeds, and rationale for the financing. This is a capital-raising measure (third-party allotment of subscription rights) and constitutes a share issue/capital change announcement rather than an earnings report, management update, or other regulatory filing. Therefore, it best fits the “Share Issue/Capital Change” category (SHA).
2026-05-20 Japanese
有価証券届出書（組込方式）
Share Issue/Capital Change Classification · 91% confidence The document is a full "有価証券届出書" (securities registration statement/prospectus) filed with the Shikoku Finance Bureau on May 20, 2026, by Medrx Co., Ltd. It details the issuance of new stock acquisition rights (warrants), the offering terms, amounts, exercise conditions, and capital raising purpose. This is not a simple announcement but the complete registration/prospectus for a new securities issuance, which falls under our Share Issue/Capital Change category (SHA).
2026-05-20 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It confirms the accuracy of the contents of the Annual Securities Report (Yuuka Shouken Houkokusho) for the fiscal year ending December 31, 2025. Since this is a formal regulatory filing required by law to accompany the annual report and does not fit into the other specific categories like 10-K or IR, it is classified as a Regulatory Filing.
2026-03-19 Japanese
有価証券報告書－第24期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the standard annual financial report filed with the Financial Services Agency (FSA) in Japan. It contains comprehensive financial statements, management discussion, and business information for the fiscal year ending December 31, 2025. This corresponds to the 10-K equivalent in the Japanese regulatory framework. FY 2025
2026-03-19 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification confirming the accuracy of a previously filed semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim/semi-annual report. H1 2025
2025-08-08 Japanese
半期報告書－第24期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Medrx Co., Ltd. with the Shikoku Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and business information for the interim period ending June 30, 2025. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-08-08 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.